FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.

FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer. - FDG-PET for prediction of the efficacy of chemoradiotherapy.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002249

Enrollment

Registered

2009-07-25

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

FDG-PET was performed before and after inductuion chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Stage II/III (Excluding T4) esophageal cancer. (2)Inclusion criteria 1)Lesion mainly located in the thoracic esophagus. Histologically proven squamous cell carcinoma. 2)No previous chemotherapy against any cancer. 3)Aged 20 to 80 years old 4)ECOG Performance status 0 or 1. 5)Written informed consent. 6)Adequate organ functions.

Exclusion criteria

Exclusion criteria: 1)Esophageal cancer spreading to pharynx or stomach. 2)Simultaneous double cancers. 3)Previous radiotherapy against cancer of thoracic cavity. 4)Uncontrollable complicating disease. 5)Interstitial pneumonia, fibroid lung. 6)History of collagen disease. 7)Psychosis. 8)Active infection which should be treated. 9)HBs antigen positive. HCV positive, TPHA positive, HIV positive 10)Women during pregnancy or breast-feeding. Men expecting to have a child.

Design outcomes

Primary

Measure	Time frame
An association between FDG-PET finding during induction chemotherapy and the efficacy of chemoradiotherapy (CR or Non-CR).	—

Secondary

Measure	Time frame
An association between FDG-PET finding during induction chemotherapy and overall survival. An association between FDP-PET finding during induction chemotherapy and disease-free survival. Safety. Optimal cut off value to predict CR Adverse event.	—

Countries

Japan

Contacts

Public ContactSachiko Yamamoto

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Gastrointestinal Oncology

yamamoto-sa@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026